Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- PRESS SEMINAR
October 6, 2003
- AnGes MG Pursuing Alliance Strategy: Prof. Morishita
October 6, 2003
- Otsuka: WATER (18O, 95%) CIL for PET
October 6, 2003
- New Relief Measures Planned for Developing Countries: JPMA
October 6, 2003
- Japanese Healthcare Q&A (1)
October 6, 2003
- BUSINESS NEWS IN BRIEF
October 6, 2003
- WEBSITE NEWS
October 6, 2003
- Chuikyo Starts Discussion to Review NHI Pricing Rule
October 6, 2003
- PFSB to Beef Up NDA Review, Safety Measures, Victim Relief via New Drug Organization
October 6, 2003
- Sanwa Kagaku Kenkyusho: Glutest Neo Blood Glucose Meter
October 6, 2003
- Revisions of Package Inserts Required for 16 Drugs, Including Ribavirin
October 6, 2003
- BULLETIN
October 6, 2003
- Korosho to Draft GL on Use, Management of Thalidomide
October 6, 2003
- WORLD NEWS IN BRIEF
October 6, 2003
- REGULATORY NEWS IN BRIEF
October 6, 2003
- Pharma Delegates to Welcome Presidents from Japanese Firms: Chairman Yamasaki
October 6, 2003
- BULLETIN
October 6, 2003
- So-net M3 to Have "MR-Kun" Enter the US Market
October 6, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 6, 2003
- Teijin Pharma Forecasts Major Growth in 2005, 2006
October 6, 2003
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…